claudin 18.2: a biomarker for gastric cancer
Published 11 months ago • 286 plays • Length 1:07Download video MP4
Download video MP3
Similar videos
-
2:17
claudin 18.2 and fgfr2b as novel targets in gastric cancer
-
1:35
assessing the prevalence of cldn18.2 in gastric/gastroesophageal cancers
-
0:51
claudin 18.2 as an emerging target in gastrointestinal cancers
-
2:08
targeting cldn18.2 with zolbetuximab in gastric and gej cancer
-
2:20
emerging approaches in targeting cldn18.2 in gastric cancer
-
1:28
advances in biomarker-directed therapies for gastric cancer
-
2:45
current and future biomarkers for gastroesophageal cancer
-
2:16
safety and efficacy of a cldn18.2-specific car t-cell therapy in gi adenocarcinoma
-
6:00
claudin18.2: an emerging biomarker and its significance as a therapeutic target in g/gej cancers
-
2:56
will zolbetuximab impact the treatment landscape for gastric cancer?
-
1:33
transtar101: osemitamab, a novel cldn18.2 inhibitor, in solid tumors
-
2:49
spotlight: zolbetuximab and m-folfox6 in cldn18.2 , her2- gej cancer
-
7:38
deliver trial: blood based biomarker analysis of patients with gastric cancer treated with nivolumab
-
2:26
micrornas as a biomarker of resistance to trastuzumab in gec
-
1:05
limitations in immune checkpoint inhibitors in treating gastric cancer
-
0:58
lb1908: a novel car-t cell therapy targeting claudin 18.2 in gi malignancies
-
1:44
what role will zolbetuximab play in treating gastric cancer?
-
1:04
what does the future hold for car-t cells in gastric cancers?
-
1:52
iilustro: zolbetuximab, mfolfox6, and nivolumab combinations for gastrointestinal cancer